Poor
Mostly Unaligned
Patient Risk:
Moderate
Summary
Many statements about muscle effects and red yeast rice/plant sterols are not supported by the provided FDA label excerpts and include mechanistic/clinical claims that conflict with what is provided. Several claims assert specific outcomes (e.g., muscle protein synthesis inhibition, negative muscle-building effects, patient anecdotes) that are not supported by the supplied prescribing information. Overall alignment is poor based solely on the excerpted label text.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels in the blood.
Supported indirectly by label mechanism/clinical indications for reducing cholesterol (12.1 Mechanism of Action; 1 INDICATIONS AND USAGE; 1.2 Hyperlipidemia).
Lipitor reduces low-density lipoprotein (LDL) cholesterol in the bloodstream.
Supported: 1.2 Hyperlipidemia (reduce LDL-C); 14.2 (reduces LDL-C).
Lipitor works by inhibiting the production of cholesterol in the liver.
Supported in concept: 12.1 Mechanism of Action describes inhibition of HMG-CoA reductase (lipid/cholesterol pathway).
Unsupported Statements
Statins, including Lipitor, have been shown to have both positive and negative effects on muscle function and growth.
Provided label excerpts discuss skeletal muscle adverse effects (myopathy/rhabdomyolysis) but do not support claims about positive effects on muscle function/growth.
Statins may increase muscle protein synthesis.
No support in provided label excerpts.
Statins may enhance muscle function by increasing blood flow.
No support in provided label excerpts.
Statins may enhance muscle function by reducing inflammation in muscles.
No support in provided label excerpts.
Statins may reduce muscle mass, particularly in individuals who are already at risk of muscle loss.
No support in provided label excerpts.
Lipitor has been shown to inhibit muscle protein synthesis.
No support in provided label excerpts.
Lipitor may reduce muscle strength, particularly in older adults.
The provided label excerpt states risk of myopathy/rhabdomyolysis and mentions withholding/discontinuing in certain conditions, but it does not support the specific claim that Lipitor may reduce muscle strength particularly in older adults.
Lipitor and other statins can have a negative impact on muscle building progress.
Label excerpted content does not support claims about “muscle building progress.”
Lipitor and other statins can inhibit muscle protein synthesis and reduce muscle strength.
No support for inhibition of muscle protein synthesis in provided label excerpts.
Some individuals have reported negative effects on muscle building progress while taking Lipitor.
No support in provided label excerpts.
A 35-year-old bodybuilder reported a significant decrease in muscle mass and strength after starting Lipitor.
No support in provided label excerpts.
A 50-year-old individual reported reduced muscle function and increased muscle soreness after taking Lipitor for several months.
No support in provided label excerpts.
Red yeast rice has been shown to lower cholesterol levels.
Not addressed in the provided label excerpts for Lipitor.
Red yeast rice has been shown to have no negative effects on muscle building (as stated in the text).
Not addressed in the provided label excerpts.
Plant sterols can help to lower cholesterol levels.
Not addressed in the provided label excerpts.
Plant sterols can help to lower cholesterol levels without inhibiting muscle protein synthesis (as stated in the text).
Not addressed in the provided label excerpts; also references “muscle protein synthesis” which is not supported for Lipitor in the provided excerpts.
Lipitor may inhibit muscle protein synthesis and reduce muscle strength.
No support for inhibition of muscle protein synthesis in provided label excerpts; the label discusses myopathy/rhabdomyolysis risk rather than “muscle protein synthesis” or a general claim about reduced muscle strength.
Contradictions
Low
AI Statement
Statins, including Lipitor, have been shown to have both positive and negative effects on muscle function and growth.
Label Reference
Provided label excerpts only support skeletal muscle adverse effects (myopathy/rhabdomyolysis) risk; they do not support “positive effects on muscle function and growth.”
Low
AI Statement
Statins may increase muscle protein synthesis.
Label Reference
Provided label excerpts do not support this; they describe rare rhabdomyolysis/myopathy risk but not increased synthesis.
Important Omissions
No label-supported description of LIPITOR indications (e.g., MI/stroke/revascularization risk reduction; hyperlipidemia LDL-C/TG/apo B reduction) was provided in the AI response text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response emphasizes speculative/unsupported mechanistic and anecdotal muscle-building claims (including muscle protein synthesis inhibition) and does not accurately reflect that the provided label excerpts focus on skeletal muscle adverse events (e.g., myopathy/rhabdomyolysis) and risk factors/drug interaction context.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Multiple claims (especially about muscle protein synthesis, muscle function/growth benefits, and specific patient anecdotes) are not supported by the provided Lipitor FDA label excerpts; additional statements about red yeast rice and plant sterols are outside the Lipitor label scope provided.
Suggested Improvement
Limit muscle-related discussion to label-supported skeletal muscle adverse event risk language (myopathy/rhabdomyolysis, risk factors, and guidance to withhold/discontinue in appropriate scenarios) and avoid mechanistic claims (e.g., muscle protein synthesis inhibition) and anecdotal reports unless explicitly present in the supplied label. Also restrict cholesterol-lowering adjunct discussions to what is present in the provided prescribing information excerpts.